Skip to NavigationSkip to content

Richard Ridinger resigns from CEO position at Lonza causing shares to plummet

Published on: 30/01/19

Richard Ridinger, the CEO of Swiss biotechnology firm Lonza Group, will step down from his position in March of this year.

The 60 year old CEO will remain with the company until the end of April and will be available to Lonza as an advisor until the end of 2019. However he will leave his role on 1 March.

Ridinger will be replaced by the company’s current President and COO Marc Funk, who joined the firm in 2008. Before joining Lonza, Funk had previously acted as Head of Corporate Law at German-firm Merck Serono. Funk also acted as Co-CEO at the Illinois-based biotech Geneprot.  

Ridinger has overseen a period of significant growth since joining the firm in 2012. Stocks in the firm plummeted on the news of Ridinger’s resignation.

Prior to joining Lonza, Ridinger served as head of Care Chemicals at Cognis Benelux BV from 2001 to 2006 and as an Executive Vice President of Care Chemicals at BASF.

Mission Statement
Pharmafile.com is a leading portal for the pharmaceutical industry, providing industry professionals with pharma news, pharma events, pharma service company listings and pharma jobs,
Site content is produced by our editorial team exclusively for Pharmafile.com and our industry newspaper Pharmafocus. Service company profiles and listings are taken from our pharmaceutical industry directory, Pharmafile, and presented in a unique Find and Compare format to ensure the most relevant matches